Peptides for Mental Health: What Every Biohacker Needs to Know Before Starting

If you are reading this, you have probably already encountered peptides in your own research, heard about them from a friend in the biohacking community, or perhaps you are already injecting something you ordered online. You are not alone. Imports of peptide compounds from China roughly doubled in 2025, and the wellness industry has embraced these molecules with an enthusiasm that far outpaces the clinical evidence supporting them.

I am a board-certified psychiatrist who specializes in integrative and metabolic psychiatry. My practice combines traditional psychiatric care with functional medicine approaches, and I work with patients who are interested in root-cause solutions to mental health challenges. Increasingly, those patients come to me already using peptides, or asking whether they should.

This post is my attempt to give you everything you need to understand before exploring peptides for mental health: why the evidence is limited, what the regulatory landscape looks like, how to source safely if you proceed, and how to evaluate the claims you will encounter. Consider this your foundation before diving into specific peptides.

Why Big Pharma Is Not Studying Peptides for Mental Health

If peptides are so promising, why are there not more clinical trials? Why has the FDA not approved any peptides specifically for anxiety or depression? The answer has less to do with science than with economics.

The Patent Problem

Pharmaceutical companies invest hundreds of millions of dollars in clinical trials because they expect to recoup those costs through patent-protected sales. A novel molecule can be patented, allowing the company exclusive rights to sell it for years. This is how the system funds drug development.

Most peptides of interest to the biohacking community are not patentable. They are either naturally occurring compounds, minor modifications of natural compounds, or molecules whose structures have been public for decades. BPC-157, for example, is derived from a protein found in human gastric juice. Selank and Semax are modifications of endogenous peptides. No company can patent these molecules and charge premium prices.

Without patent protection, there is no financial incentive to run the expensive trials required for FDA approval. Phase III trials for psychiatric medications typically cost $100-300 million and take years to complete. No rational business will make that investment for a compound anyone can manufacture.

The GLP-1 Halo Effect

The spectacular success of GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) has created what researchers call a halo effect. These peptide-based medications have proven effective for diabetes and obesity, generating billions in revenue and transforming how the public thinks about injectable therapies.

However, the success of GLP-1s does not validate other peptides. GLP-1 agonists went through rigorous clinical development with large, well-designed trials. They work through specific, well-characterized receptor mechanisms. Extrapolating from their success to assume that other peptides must also work is a logical error that wellness marketers exploit constantly.

As Dr. Eric Topol of Scripps Research has noted, people are generalizing the success of GLP-1s to a multitude of untested peptides, thereby exposing themselves to contamination and long-term health dangers. This is unfounded and reckless.

The Russian Research Paradigm

Several peptides discussed in this series, including Selank and Semax, were developed in Russia and are approved there for clinical use. This raises an obvious question: if they are approved somewhere, does that mean they work?

The Russian approval process differs significantly from FDA standards. Trials are often smaller, with less rigorous methodology. Many studies are published only in Russian journals and have not been replicated by independent Western researchers. This does not mean the research is fraudulent, but it does mean we should interpret it cautiously.

When I review a peptide with Russian approval, I consider it a signal worth investigating rather than proof of efficacy. The research suggests biological activity and relative safety, but it does not meet the evidentiary bar we would require for a psychiatric medication in the United States.

The Regulatory Landscape: FDA, Compounding Pharmacies, and the Gray Market

The regulatory status of peptides in the United States is genuinely confusing. Some peptides are FDA-approved medications. Others are banned from compounding. Many exist in a legal gray zone where personal possession is permitted but sale for human use is not.

The FDA Crackdown of 2023

In 2023, the FDA added nearly 20 peptides to its list of substances that should not be compounded due to safety risks. This list includes several compounds popular in the biohacking community, including BPC-157, which the World Anti-Doping Agency had already banned in 2022.

The FDA’s stated rationale centers on three concerns: risk of immunogenicity (immune reactions), peptide-related impurities from manufacturing, and limited safety-related information. This action triggered immediate pushback, with compounding pharmacies filing lawsuits arguing that the FDA had skipped legally required procedural steps.

The Legal Gray Zone

The current legal situation is complex:

• FDA-approved peptides (insulin, certain growth hormones, GLP-1 agonists) are legal with a prescription and have undergone rigorous safety testing
• Compounded peptides were available through specialized pharmacies until the FDA restrictions; some are now off-limits, others remain in legal limbo
• Research peptides are sold labeled “for research use only” and “not for human consumption,” a labeling widely understood as a legal fiction
• Personal use of most peptides remains legal; you can possess BPC-157, but it cannot legally be sold for human consumption in the United States

The Gray Market Reality

With legitimate compounding sources restricted, many people have turned to unregulated suppliers. U.S. customs data shows that imports of hormone and peptide compounds from China roughly doubled in 2025. These products come from manufacturers not subject to FDA quality standards.

The risks of this gray market are not theoretical. Dosing can be off by 10-90 percent. Contamination with bacteria, heavy metals, or other substances has been documented. There is no quality control, sterility standards, or purity testing requirement. What is in the vial may not match what the label claims.

The Political Dimension

The peptide regulatory landscape may be shifting. Robert F. Kennedy Jr. has publicly promised to end what he calls the FDA’s war on peptides, stem cells, and other alternative treatments. The FDA recently removed experts from compounding advisory panels, potentially paving the way for more peptide-friendly appointees.

Regardless of your political views, it is worth noting that regulatory changes driven by ideology rather than evidence could increase access while doing nothing to address quality and safety concerns. Easier access to contaminated products is not a win for patients.

Harm Reduction: If You Are Going to Use Peptides, Read This

If you have decided to use peptides despite the regulatory uncertainty and evidence limitations, the most immediate risk you face is not the peptide itself. It is what else might be in the vial.

The Contamination Reality

Peptides from unregulated sources operate entirely outside the quality control systems that protect pharmaceutical supply chains. As one researcher noted, it is really a choose-your-own-adventure. It is up to the chemical companies that are making these things to figure out quality control, good manufacturing practices, testing for Certificates of Analysis, verifying that there are no contaminants, heavy metals, pesticides, whatever. It is anybody’s guess what is really happening with the quality control of these unregulated peptides.

Documented contamination issues include bacterial contamination from non-sterile manufacturing, heavy metal residues, incorrect peptide sequences or degraded product, dramatically incorrect dosing (10-90 percent variance), and undisclosed additives or entirely different compounds.

Understanding Certificates of Analysis

Reputable suppliers provide Certificates of Analysis (COAs) documenting third-party testing results. However, COAs are only as good as the testing behind them.

A meaningful COA should include: identity confirmation via mass spectrometry showing the correct peptide sequence; purity testing, typically via HPLC, showing percentage of target compound; sterility testing for injectable products; endotoxin testing (bacterial contamination byproducts); and batch-specific results matching the product you received.

Red flags in COAs include: generic COAs not tied to specific batch numbers; testing from in-house labs rather than independent third parties; missing sterility or endotoxin testing for injectables; purity claims without supporting data; and inability to verify the testing lab exists.

Supplier Red Flags

Beyond COA quality, certain supplier characteristics should raise concerns:

• Making specific medical claims about treating diseases
• Providing dosing advice or medical guidance (legally prohibited)
• Prices dramatically below market rates
• No verifiable business address or contact information
• Payment only via cryptocurrency or wire transfer

Safe Handling Practices

If you are using injectable peptides, proper technique reduces infection risk:

For reconstitution: Use bacteriostatic water (contains preservative) rather than sterile water for multi-use vials. Add water slowly down the side of the vial; never shake. Swirl gently until fully dissolved.

For storage: Store lyophilized (powder) peptides in freezer. Store reconstituted peptides in refrigerator. Use reconstituted peptides within manufacturer’s recommended timeframe, typically 2-4 weeks.

For injection technique: Always use new, sterile syringes and needles. Clean vial stopper with alcohol before drawing. Clean injection site with alcohol and allow to dry. Rotate injection sites to prevent tissue damage. Never share supplies.

When to Involve a Physician

Even if your physician does not prescribe peptides, there are good reasons to inform them: drug interactions with your current medications can be assessed; baseline labs can establish pre-use health markers; adverse reactions can be properly documented and treated; and your complete medical picture informs better care.

Many patients fear judgment from their doctors. In my experience, physicians who work in integrative medicine are accustomed to these conversations. If your current physician dismisses your questions without engagement, that may be a sign to find one who will meet you where you are.

How to Evaluate Peptide Research: Separating Hype from Evidence

The peptide space is flooded with claims that sound scientific but collapse under scrutiny. Understanding how to evaluate research will help you distinguish genuine promise from marketing dressed up as science.

The Evidence Hierarchy

Not all evidence is equal. Here is how different types rank, from weakest to strongest:

Mechanism speculation: Claims about how a peptide should work based on its structure or related compounds. This is hypothesis, not evidence.

In vitro studies: Experiments on cells in a dish. Many compounds that work in cells fail in living organisms.

Animal studies: Experiments in mice, rats, or other animals. Better than cell studies, but roughly 90 percent of compounds that work in animals fail in human trials.

Small controlled trials: Studies with 20-50 participants and a control group. Better, but results may not replicate in larger populations.

Large randomized controlled trials: Studies with hundreds or thousands of participants, randomized to treatment or placebo. The gold standard.

Most peptide evidence sits in the middle of this hierarchy: animal studies and small human trials. That is not nothing, but it is far from proof.

The Mouse Problem

A striking amount of peptide research involves rodent models. When you read that a peptide showed anxiolytic effects or antidepressant activity, there is a good chance the subjects were mice or rats.

Why mouse studies mislead: Mouse metabolism differs dramatically from human metabolism. Mouse models of depression and anxiety are artificial constructs that may not reflect human conditions. Dosing cannot be directly extrapolated from mice to humans. Historically, about 90 percent of drugs that work in animal models fail in human trials. Publication bias means failed mouse studies often go unpublished.

When I see claims based entirely on animal research, I consider the peptide interesting but unproven for human use.

Sample Size Matters

Many human peptide trials involve 20-30 participants. While these studies can detect signals, they lack statistical power to establish reliable effects. A trial with 30 participants might show a positive result purely by chance. Small studies also cannot detect rare side effects. If a peptide causes a serious adverse event in 1 in 200 people, a 30-person trial is unlikely to observe it.

For psychiatric medications, Phase III trials typically involve hundreds to thousands of participants across multiple sites. This is the scale needed to establish efficacy and safety with confidence. Almost no peptide has this level of evidence for mental health applications.

The Placebo Effect in Self-Experimentation

When you pay money for a compound, inject it, and expect improvement, you are primed to perceive benefits. This is not weakness; it is basic psychology that affects everyone.

The placebo effect in psychiatric conditions is particularly strong. In antidepressant trials, placebo response rates of 30-40 percent are common. People given inert pills genuinely feel better. Biohacking communities compound this problem through confirmation bias and social reinforcement. People who have positive experiences share them. People who notice nothing tend to stay quiet.

Questions to Ask About Any Peptide Claim

When evaluating peptide research or claims, ask:

1. Was this studied in humans or just animals?
2. How many people were in the study?
3. Was there a placebo control group?
4. Were participants and researchers blinded to who received treatment?
5. Has the study been replicated by independent researchers?
6. Who funded the research? Do they profit from positive results?
7. Was it published in a peer-reviewed journal or just on a company website?

My Clinical Stance

I do not prescribe unregulated peptides. However, I do work with patients who are using them. My job is not to judge; it is to reduce harm and provide honest information. When a patient brings me their peptide protocol, I help them understand what the evidence actually shows, what risks they may be taking, and how to make more informed choices.

The lack of large-scale trials does not mean peptides are ineffective. It means we do not know whether they are effective. This is an important distinction. Absence of evidence is not evidence of absence, but it is also not evidence of efficacy.

Armed with this foundation, you are ready to evaluate the specific peptides covered in the following posts. We will begin with Selank, the anxiety peptide with perhaps the strongest case among those popular in the biohacking community.